{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:47Z","timestamp":1793320607226,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.dld.2012.02.005","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T18:47:31Z","timestamp":1332874051000},"page":"610-616","source":"Crossref","is-referenced-by-count":53,"title":["Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Thomas","family":"Decaens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Roudot-Thoraval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie Serge","family":"Zafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Mallat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Duvoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.dld.2012.02.005_bib0005","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2012.02.005_bib0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1470-2045(04)01508-6","article-title":"Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum","volume":"5","author":"Burroughs","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/156800909788166556","article-title":"The applicability of mTOR inhibition in solid tumors","volume":"9","author":"Konings","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.dld.2012.02.005_bib0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2012.02.005_bib0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2006.11.021","article-title":"Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma","volume":"46","author":"Semela","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2012.02.005_bib0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/hep.22685","article-title":"Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice","volume":"49","author":"Lang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.02.005_bib0035","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2012.02.005_bib0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2008.03.024","article-title":"Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma","volume":"49","author":"Piguet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2012.02.005_bib0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s11307-009-0213-4","article-title":"Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model","volume":"11","author":"Ong","year":"2009","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.dld.2012.02.005_bib0050","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2012.02.005_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2012.02.005_bib0060","article-title":"Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma","author":"Baba","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2012.02.005_bib0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.20774","article-title":"Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma","volume":"103","author":"Nakanishi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2012.02.005_bib0070","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"mTOR and P70 S6 kinase expression in primary liver neoplasms","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2012.02.005_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2007.08.018","article-title":"Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection","volume":"48","author":"Schmitz","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2012.02.005_bib0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.tp.0000252780.42104.95","article-title":"Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation","volume":"83","author":"Sieghart","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2012.02.005_bib0085","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.TP.0000154913.88193.FF","article-title":"Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil","volume":"79","author":"Elsharkawi","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2012.02.005_bib0090","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.transproceed.2005.03.013","article-title":"Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation","volume":"37","author":"Stippel","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2012.02.005_bib0095","first-page":"25","article-title":"Effects of rapamycin in liver transplantation","volume":"7","author":"Chen","year":"2008","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.dld.2012.02.005_bib0100","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","article-title":"Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma","volume":"10","author":"Kneteman","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2012.02.005_bib0105","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2012.02.005_bib0110","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3748\/wjg.v12.i19.3114","article-title":"Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience","volume":"12","author":"Zhou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2012.02.005_bib0115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.21420","article-title":"Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"14","author":"Zimmerman","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2012.02.005_bib0120","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.02.005_bib0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2012.02.005_bib0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0135","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/he.2000.5628","article-title":"Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators","volume":"31","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.02.005_bib0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2012.02.005_bib0145","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O\u2019Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0150","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2012.02.005_bib0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0165","first-page":"1659","article-title":"Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas","volume":"46","author":"Wong","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.dld.2012.02.005_bib0170","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2012.02.005_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.dld.2012.02.005_bib0180","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2012.02.005_bib0185","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","article-title":"Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer","volume":"13","author":"Rizell","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0190","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0200","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2012.02.005_bib0205","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.20.9908","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study","author":"Zhu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0210","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","article-title":"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study","volume":"10","author":"Faivre","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2012.02.005_bib0215","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-09-0465","article-title":"A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas","volume":"15","author":"Bekaii-Saab","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2012.02.005_bib0220","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2012.02.005_bib0225","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice","volume":"98","author":"Podsypanina","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.dld.2012.02.005_bib0230","first-page":"5027","article-title":"Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779","volume":"62","author":"Shi","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.dld.2012.02.005_bib0235","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0168-8278(00)80248-2","article-title":"Positron emission tomography scanning in the evaluation of hepatocellular carcinoma","volume":"32","author":"Khan","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2012.02.005_bib0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1078-0432.CCR-06-1357","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma","volume":"13","author":"Seo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2012.02.005_bib0245","first-page":"1811","article-title":"In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET","volume":"36","author":"Torizuka","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.dld.2012.02.005_bib0250","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2407-6-110","article-title":"Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma","volume":"6","author":"Yang","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2012.02.005_bib0255","first-page":"326A15","article-title":"Final results of a phase II study with sunitinib malate in advanced hepatocellular carcinoma","volume":"52","author":"Basso","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2012.02.005_bib0260","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865812000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865812000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T22:23:31Z","timestamp":1543098211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865812000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1590865812000606"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2012.02.005","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}